10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2018 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2018 10-K (Filed: Feb 7, 2019) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2018 | Dec 31, 2017 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 1,467,700 | 812,700 |
| Marketable securities | 1,342,200 | 596,800 |
| Accounts receivable - trade, net | 1,723,700 | 1,538,600 |
| Accounts receivable from Sanofi | 226,400 | 193,700 |
| Accounts receivable from Bayer | 293,100 | 242,000 |
| Inventories | 1,151,200 | 726,100 |
| Prepaid expenses and other current assets | 243,300 | 225,100 |
| Total current assets | 6,447,600 | 4,335,000 |
| Marketable securities | 1,755,000 | 1,486,500 |
| Property, plant, and equipment, net | 2,575,800 | 2,358,600 |
| Deferred tax assets | 828,700 | 506,300 |
| Other noncurrent assets | 127,400 | 77,900 |
| Total assets | 11,734,500 | 8,764,300 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 218,200 | 178,200 |
| Accrued expenses and other current liabilities | 772,100 | 637,200 |
| Deferred revenue, current | 452,500 | 320,100 |
| Total current liabilities | 1,442,800 | 1,135,500 |
| Capital and facility lease obligations | 708,500 | 703,500 |
| Deferred revenue, noncurrent | 464,200 | 629,200 |
| Other noncurrent liabilities | 361,700 | 152,000 |
| Total liabilities | 2,977,200 | 2,620,200 |
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Preferred Stock, $.01 par value; 30,0000,000 shares authorized; issued and outstanding - none | 0 | 0 |
| Additional paid-in capital | 3,911,600 | 3,512,900 |
| Retained earnings | 5,254,300 | 2,946,700 |
| Accumulated other comprehensive (loss) income | (12,300) | 600 |
| Treasury Stock, at cost; 3,990,021 shares in 2018 and 3,763,868 shares in 2017 | (396,400) | (316,200) |
| Total stockholders' equity | 8,757,300 | 6,144,100 |
| Total liabilities and stockholders' equity | 11,734,500 | 8,764,300 |
| Project | ||
| Sanofi | ||
| Deferred revenue, current | 246,700 | 177,700 |
| Deferred revenue, noncurrent | 279,300 | 379,900 |
| Other | ||
| Deferred revenue, current | 205,800 | 142,400 |
| Deferred revenue, noncurrent | 184,900 | 249,300 |
| Class of Stock | ||
| Class A Stock | ||
| Common stock | 0 | 0 |
| Total stockholders' equity | 0 | 0 |
| Common Stock | ||
| Common stock | 100 | 100 |
| Total stockholders' equity | 100 | 100 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2018 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |